Fig. 2
A The mean LogMAR BCVA values from baseline visit to week 48 visit for the patients treated with brolucizumab and aflibercept. B The mean CMT values from baseline to week 48 for the patients treated with brolucizumab and aflibercept
Fig. 2 | International Journal of Retina and Vitreous